骨性Ⅱ类错[牙合]2种不同矫治技术的PAR指数比较

目的应用PAR指数评价传动直丝弓矫治技术与MBT滑动直丝弓矫治技术在骨性Ⅱ类错[牙合]拔牙患者的矫治效果。方法30例安氏Ⅱ类Ⅰ分类错[牙合]患者,分别使用传动直丝弓技术矫治15例（A组）、MBT滑动直丝弓矫治15例（B组）,于治疗前、后对模型进行PAR指数测定,并进行统计分析。结果A组治疗前、后加权PAR总分值减少率（92．26±3．15）％,B组为（93．78±2．58）％,2组间差异无统计学意义（P〉0．05）;A组矫治疗程为（20．6±2．8）个月,B组为（22．3士3．1）个月,差异有统计学意义（P〈0．05）。结论应用传动直丝弓技术矫治或MBT滑动直丝弓矫治技术均可使安氏Ⅱ类Ⅰ分类错[牙合]得到较大改善。     

无托槽隐形矫治器与直丝弓矫治器对成人牙周炎继发错牙合畸形矫治效果的对比研究

探讨成人牙周炎继发错牙合畸形采用不同矫治器的效果。选取68例于2013年5月~2014年5月期间我院接收的牙周炎继发错牙合畸形患者,随机分为对照组(给予直丝弓矫治器治疗,n=34)和观察组(给予无托槽隐形矫治器治疗,n=34),观察两组患者的矫治效果。正畸治疗后,观察组患者的ABO评分与对照组基本一致,无明显差异性(P0.05);治疗后,观察组PLI显著高于治疗前(P0.05),GI、SBI、CAL均低于对照组(P0.05),而对照组各牙周健康指数均较治疗前显著要高(P0.05)。牙周炎继发错牙合畸形采用直丝弓矫治器和无托槽隐形矫治器治疗疗效相似,但后者更有利维持患者牙周健康,因此值得广泛推广。     

多曲方丝弓联合直丝弓矫治器矫治骨性安氏Ⅲ类错[牙合]

目的探讨多曲方丝弓联合直丝弓矫治器矫治骨性安氏Ⅲ类错[牙合]的临床效果。方法恒牙期骨性安氏Ⅲ类错[牙合]9例,采用多曲方丝弓技术联合直丝弓矫治器矫治,矫治至前牙反殆解除,尖牙磨牙为中性关系,治疗前、后拍摄头颅侧位定位片,进行X线头影测量分析,治疗前、后取模,并进行模型分析。结果矫治后UI—LI、FH—MP、OP—MP、FMIA、OB、OJ、OP—MP、UL-SnPg’距LL-SnPg’距二者差值较矫治前增大（P〈O．01）,LI—NB、IMPA、LI—MP、较矫治前减少（P〈0．01）;矫治前、后FMA、APDI、PG-NB、Yaxis、ODI、SNA、SNB比较差异无统计学意义（P〉0．05）;颌骨基本无变化。结论在直丝弓矫治器中使用多曲方丝弓技术矫治骨性安氏Ⅲ类错[牙合]效果明显。     

直丝弓矫正器联合多曲方丝弓技术矫治AG前牙开(牙合)的临床探讨

目的:评价多曲方丝弓技术(MEAW)联合直丝弓矫正器矫治前牙开(耠)的效果.方法:应用MEAW联合直丝弓矫正器对7例严重前牙开(牙合)病例进行矫治,并对治疗前后头颅侧位片进行测量分析.结果:经过14～24个月治疗后,7例患者前牙开(牙合)得到矫治,后牙为尖窝交替关系,侧貌明显改善.结论:直丝弓矫治器联合MEAW能有效地治疗严重前牙开(牙合),并能缩短矫治时间,值得临床推广.     

传动直丝弓矫正技术及口外弓支抗矫治安氏Ⅱ类Ⅰ分类错[牙合]畸形的对比分析

选取我院收治的41例安氏Ⅱ类Ⅰ分类错[牙合]畸形患者作为研究对象,将其随机分成两组,治疗A组21例,采用传动直丝弓矫正技术,拔出上颌第一前磨牙或者下颌第一/第二前磨牙;治疗B组20例,采用口外弓支抗矫治技术,拔出牙齿位置同治疗A组。治疗前后对患者行X线头影测量,对比分析两组临床疗效。结果治疗A组平均治疗时间为14.1±0.7个月,治疗B组平均治疗时间为19.2±1.2个月,差异显著（P〈0.05）,具有统计学意义;两组患者X线头影测量结果差异显著（P〈0.05）,具有统计学意义。相对于口外弓支抗矫治技术,传动直丝弓矫正技术治疗安氏Ⅱ类Ⅰ分类错[牙合]畸形的治疗周期短,治疗效果显著,值得临床推广应用。     

直丝弓矫正器联合多曲方丝弓技术矫治前牙开[牙合]的临床探讨

目的：评价多曲方丝弓技术（MEAW）联合直丝弓矫正器矫治前牙开[牙合]的效果。方法：应用MEAW联合直丝弓矫正器对7例严重前牙开病例进行矫治,并对治疗前后头颅侧位片进行测量分析。结果：经过14～24个月治疗后,7例患者前牙开[牙合]得到矫治,后牙为尖窝交替关系,侧貌明显改善。结论：直丝弓矫治器联合MEAW能有效地治疗严重前牙开[牙合],并能缩短矫治时间,值得临床推广。     

直丝弓矫正技术对替牙期牙齿畸形的矫正效果观察

目的观察直丝弓矫正技术对替牙期牙齿畸形的矫正效果。方法选择2010年2月-2012年12月我院口腔科收治的100例错颌畸形患者为研究对象。随机分为试验组和对照组各50例。试验组行直丝弓矫正技术治疗,对照组行不锈钢丝矫正技术治疗,对比观察两组畸形矫正情况。结果试验组治疗总有效率为98.0%,明显高于对照组56.0%,差异有统计学意义（P〈0.05）。试验组并发症发生率为6.0%,明显低于对照组的34.0%,差异有统计学意义（P〈0.05）。结论使用直丝弓矫正技术可持久有效矫正替牙期牙齿畸形,操作简洁,并发症少,值得临床推广使用。     

Z2直丝弓矫治器治疗错颌畸形34例疗效分析

目的探讨Z2直丝弓矫治器治疗错颌畸形的临床疗效及矫治要点。方法 34例错颌畸形患者均采用Z2直丝弓矫治器进行矫治,分析临床矫治步骤和特点。结果本组矫治时间11～27(19±2)个月,其中不拔牙矫治10例,疗程11～17(14±4)个月,拔牙矫治24例,疗程17～27(21±1)个月;矫治后患者上、下牙齿排列整齐,前牙覆颌、覆盖正常,后牙咬合关系良好。结论 Z2直丝弓矫治器用于各类错颌畸形的矫治,可精确控制牙齿位移,在减少弓丝弯制、控制支抗等方面有优势。     

微螺钉种植体支抗结合MBT直丝弓矫治技术治疗安氏Ⅱ类上颌前突错(牙合)的有效性探究

目的探究对安氏Ⅱ类上颌前突错(牙合)患者实施微螺钉种植体支抗结合MBT直丝弓矫治技术的临床效果。方法随机将2016年3月～2018年8月我院收治的56例安氏Ⅱ类上颌前突错(牙合)患者分为观察组和对照组各28例。观察组应用微螺钉种植体支抗结合MBT直丝弓矫治技术治疗,对照组应用传统支抗结合MBT直丝弓矫治技术治疗。对比两组患者颌骨、上颌牙齿位置与角度、软组织等改变情况。结果治疗后,观察组患者SNA角、SNB角、ANB角、GoGn-SN角与对照组比较,无显著差异(P0.05),但OP-SN角明显小于对照组(P0.05);治疗后,观察组患者U1-NA距、Apg-U1距、Ptm-U6距明显小于对照组(P0.05);治疗后,观察组患者U lip-E、L lip-E与对照组比较,无显著性差异(P0.05),但Z角明显大于对照组(P0.05)。结论对安氏Ⅱ类上颌前突错(牙合)患者实施微螺钉种植体支抗结合MBT直丝弓矫治技术治疗,具有较好的效果,更有助于上颌切牙内收,减小上下唇突度。     

骨性Ⅱ类错2种不同矫治技术的PAR指数比较

目的应用PAR指数评价传动直丝弓矫治技术与MBT滑动直丝弓矫治技术在骨性Ⅱ类错拔牙患者的矫治效果。方法 30例安氏Ⅱ类Ⅰ分类错患者,分别使用传动直丝弓技术矫治15例(A组)、MBT滑动直丝弓矫治15例(B组),于治疗前、后对模型进行PAR指数测定,并进行统计分析。结果 A组治疗前、后加权PAR总分值减少率(92.26±3.15)%,B组为(93.78±2.58)%,2组间差异无统计学意义(P>0.05);A组矫治疗程为(20.6±2.8)个月,B组为(22.3±3.1)个月,差异有统计学意义(P<0.05)。结论应用传动直丝弓技术矫治或MBT滑动直丝弓矫治技术均可使安氏Ⅱ类Ⅰ分类错得到较大改善。     

方丝弓矫治器结合后牙(牙合)垫矫治反(牙合)伴偏的临床观察

反伴有偏合畸形对患者美观、发音、咀嚼功能和心理均有不良影响。对此类患者单独使用活动矫治器或固定矫治器效果都不太理想,我们采用方丝弓矫治器结合后牙殆垫进行颌间不对称牵引治疗了18例反殆伴有偏畸形的患者,取得了较好的效果。     

普米克令舒治疗轻中度支气管哮喘患儿临床疗效分析

目的分析普米克令舒治疗轻中度支气管哮喘患儿的临床疗效,以及对血清基质金属蛋白酶(MMP)、基质金属蛋白酶组织抑制剂1(TIMP-1)水平及肺功能的影响。方法选择我院2017年3月～2018年3月收治支气管哮喘患儿118例作为研究对象,依照随机数字表法分为观察组和对照组各59例。对照组采用硫酸沙丁胺醇溶液吸入治疗,观察组在对照组基础上加用普米克令舒治疗,比较两组患儿疗效,记录治疗后血清MMP、TIMP-1相关因子水平及肺功能相关指标变化。结果观察组的治疗总有效率为91.53%,显著高于对照组的77.97%,差异有统计学意义(P0.05);治疗后,两组患儿的MMP-2、MMP-3、MMP-9及TIMP-1水平较治疗前均显著下降,差异有统计学意义(P0.05),且观察组上述指标均低于对照组,差异有统计学意义(P0.05);治疗后,两组患儿FEV1、FVC、PEF、V25和V50水平较治疗前均显著升高,差异有统计学意义(P0.05),且观察组上述指标均高于对照组,差异有统计学意义(P0.05)。结论普米克令舒更有效缓解轻中度哮喘患儿的症状,有效改善哮喘血清MMP、TIMP-1相关因子及肺功能相关指标,有临床治疗价值。     

口腔矫正器和持续正压气道通气治疗轻中度OSAHS疗效比较的Meta分析

目的系统评价口腔矫正器和持续正压气道通气比较治疗轻中度睡眠呼吸暂停低通气综合征（OSAHS）的疗效。方法计算机检索PubMed、EMbase、qheCochraneLibrary、CBM、VIP、WanFangData及CNKI,查找公开发表及未发表的有关口腔矫正器（OA）和持续正压气道通气（CPAP）比较治疗OSAHS疗效的随机对照试验（RCT）,检索时限均为建库至2012年11月30日,并查找相关会议论文文献,文种和发表时间不限。由2位评价者根据纳入与排除标准独立筛选文献,提取资料并评价质量后,采用RevMan5．1软件进行Meta分析,并采用GRADEpro3．6软件评价证据质量。结果最终纳入7个RCT。Meta分析结果湿示：①CPAP在改善轻中度OSAHS患者睡眠呼吸暂停低通气指数的作用更显著,其差异具有统计学意义[WMD=9．13,95％CI（8．77,9．50）,P〈0．00001];②OA和CPAP在改善轻中度OSAHS患者主观白天嗜睡方面,差异无统计学意义[WMD=0．00,95％CI（-0．12,O．12）,P=0．97]。结论与OA相比,CPAP在改善轻中度OSAHS患者睡眠呼吸暂停低通气指数的作用更显著,但在改善患者主观白天嗜睡方面无显著差异。受纳入研究质量与数量所限,上述结论尚需开展更多高质量RCT加以验证。     

Clinical Relevance of Efficacy Endpoints in OTC Headache Trials

Objective.— This analysis evaluates and ranks efficacy endpoints often used in headache trials concerning their clinical relevance in relation to the patient-related criterion “global assessment of overall efficacy” based on data gained in a large trial investigating different over-the-counter drugs in the treatment of headache. Background.— The original study showed a significant superiority of the fixed combination of acetylsalicylic acid+ paracetamol+caffeine over the combination without caffeine, the single preparations, and placebo in the treatment of headache. Methods.— For 1734 patients included in the efficacy analysis we investigated the correlation of patient's global efficacy assessment with the endpoints “time to 50% pain relief” (primary endpoint), “time to be pain-free,” pain intensity difference, sum of pain intensity difference, and extent of impairment of daily activities. Patients recorded pain intensity on a visual analog scale. Efficacy, tolerability, and extent of impairment of daily activity were assessed on verbal rating scales. A logistic regression, proportional odds model was adapted to the time to event data. Results.— The highest correlation with patient's global efficacy assessment was demonstrated for the primary endpoint time to 50% pain relief (r = 0.6727) and the sum of pain intensity difference (r = 0.7037). The frequency distribution of patient's global efficacy assessment depended primarily on the time to 50% pain relief and similarly, but to a somewhat lesser extent, on the reduction of pain intensity to 10 mm as assessed on the visual analog scale. More than 86% of the patients assessed efficacy as very good or good when their pain was reduced by 50% at least within 1 hour after drug intake. The patients accept a longer time span than 2 hours for reaching no pain to give a positive global evaluation of efficacy. Conclusions.— The time to 50% pain relief proved to be the best predictor for the global assessment of efficacy by the patient and is a useful endpoint for a univariate analysis.     

Clinical Efficacy and Safety of Lower-Dose Indapamide Therapy in the Treatment of Patients with Mild to Moderate Hypertension

Previous clinical studies with indapamide, an indoline antihypertensive drug with diuretic and vasodilating activities, have shown a dose relationship associated with potassium loss. Two placebo-controlled, randomized, double-blind, parallel clinical studies were, therefore, done to evaluate the safety and efficacy of a low dose (1.25 mg) of indapamide and to determine if an improved safety profile could be produced while maintaining efficacy with a 1.25-mg dose in patients with mild to moderate essential hypertension. Four hundred seventeen (417) adult patients with mild to moderate essential hypertension (sitting diastolic blood pressure greater-than-or-equal 95 mmHg and less-than-or-equal 110 mmHg) were enrolled in two clinical studies; 209 patients were randomized to indapamide 1.25 mg and 208 patients to placebo. Patients received single-blind placebo for a 4-week washout period followed by an 8-week double-blind treatment period during which patients received either indapamide 1.25 mg or placebo. The primary efficacy endpoint was the mean change from baseline to week 8 in sitting diastolic blood pressure. Secondary efficacy variables were the proportion of patients whose sitting diastolic blood pressure had decreased greater-than-or-equal 10 mmHg and/or had a sitting diastolic blood pressure of less-than-or-equal 90 mmHg (treatment success) at all visits and at endpoint, mean changes from baseline in sitting diastolic blood pressure at designated timepoints and at endpoint, and mean changes from baseline in standing diastolic blood pressure and in sitting and standing systolic blood pressure at all visits and at endpoint. Results of these trials were pooled in order to have a larger patient population in an attempt to detect trends not readily apparent with a smaller sample size. In the primary analysis, indapamide produced statistically significantly (p = 0.0001) greater reductions in sitting diastolic blood pressure than placebo after 8 weeks of therapy. In the secondary analysis, the percentage of indapamide-treated patients who achieved treatment success after 8 weeks of therapy was statistically significantly (p < 0.0001) higher compared to placebo-treated patients. In addition, indapamide produced a statistically significantly (p = 0.0001) superior reduction compared to placebo in sitting systolic and standing systolic and diastolic blood pressure after 8 weeks of therapy. The incidence of drug-related adverse events between patients in the indapamide and placebo groups was similar. There were no clinically meaningful differences in laboratory values, including serum potassium, between the patients in the indapamide and placebo groups. Low-dose (1.25 mg) indapamide proved to be safe and effective in the treatment of mild to moderate hypertension.     

小儿肺炎合剂的制备及临床应用

目的 建立小儿肺炎合剂的制备方法及质量控制标准,并初步观察其临床疗效。方法 对处方药物成分进行定性鉴别,并通过给药前后对照考察患儿197例。结果 临床总有效率为94．7％。结论 小儿肺炎合剂对小儿肺炎及急性呼吸道感染有显著疗效。     

A Study of the Efficacy and Safety of Moexipril in Mild to Moderate Hypertension

This placebo-controlled, double-blind, multicenter study examined the efficacy, safety, and tolerability of the angiotensin-converting enzyme inhibitor, moexipril, in lowering blood pressure in mildly to moderately hypertensive patients. Patients were initially randomized into four groups, two of which received moexipril 7.5 mg per day and two received moexipril 15 mg per day, for first 12 weeks of treatment. Patients then entered a withdrawal phase with one of the groups in each dose category continuing that dose of moexipril and one receiving placebo for 12 more weeks. From 223 patients randomized initially, 190 completed the 12-week withdrawal phase. In the two dosage groups from baseline to 12 weeks, sitting diastolic blood pressure decreased from 101.1 to 92.8 mm Hg for the 7.5-mg group and from 100.7 to 91.3 mm Hg for the 15-mg group (p < 0.05 baseline to week 12 in both groups) with a significant difference between those groups attained at week 12 only (p = 0.03). By the end of the withdrawal phase (24-week evaluation), the group that continued to receive 7.5 mg moexipril decreased diastolic blood pressure by 8.2 mm Hg, whereas the corresponding placebo group decreased diastolic blood pressure by 3.7 mm Hg. Although the difference between these two groups was not significant at the 24-week end point, all other time points differed significantly between groups at p less-than-or-equal 0.017. Similarly, whereas the corresponding placebo group had a mean reduction in diastolic blood pressure of 4.6 mm Hg, the group that continued 15 mg of moexipril showed a mean diastolic blood pressure reduction of 10.6 mm Hg (p < 0.001 between groups). No comparison between the two moexipril dosage groups was significant, however, during the withdrawal phase. These results during medication withdrawal indicate that moexipril is effective in significantly lowering diastolic blood pressure.     

亚低温治疗重症脑卒中30例疗效分析

目的：研究亚低温（Mild Hypothermia，MHT）对重症脑卒中的临床疗效及安全性。方法：2002年1月至2005年1月本科共收治60例重症脑卒中患者，随机分为亚低温治疗组（MHT＋常规治疗）30例和对照组各30例，观察其临床疗效及安全性。结果：亚低温治疗组病人神经功能缺损评分较对照组显著上升，而死亡率较对照组显著下降，P〈0．05，且无严重不良反应。结论：亚低温对重症脑卒中具有肯定的脑保护作用，可提高生存质量，降低病死率。     

利巴韦林气雾剂与注射剂治疗普通手足口病疗效观察

目的:探讨利巴韦林气雾剂局部喷射与静脉滴注治疗手足口病普通病例的疗效。方法:将2013年4月至2013年8月确诊的手足口病普通病例患儿111例按就诊时间依次分为对照组和治疗组,两组均在常规治疗的基础上,对照组给予利巴韦林注射液静脉滴注,治疗组给予利巴韦林气雾剂治疗,观察两组临床疗效和不良反应。结果:治疗组的口腔溃疡与皮疹消退时间明显短于对照组(6.5±1.1d vs 7.4±1.6 d,P0.05),但两组退热时间无明显差异(1.0±0.4 d vs 1.0±0.6 d,P0.05)。结论:与利巴韦林静脉滴注相比,利巴韦林气雾剂在治疗手足口病普通病例具有更好的临床效果。